Currently, three GPIIb/IIIa antagonists are available: abciximab, eptifibatide and tirofiban. Abciximab is a noncompetitive irreversible inhibitor of GPIIb/IIIa. It is the humanized chimeric Fab ...

Bare-metal stent implantation with abciximab pretreatment is a recommended reperfusion strategy for acute ST-segment elevation myocardial infarction (STEMI). Although sirolimus-eluting stents ...

The ReoPro Retavase Reperfusion of Stroke Safety Study (ROSIE) is an NIH-sponsored Phase II trial evaluating intravenous reteplase in combination with abciximab for the treatment of patients with ...